Want to see XFOR full AI Analyst Report?
XFOR Stock Chart & Stats
$4.17
$0.09(2.34%)
At close: 4:00 PM EDT
$4.17
$0.09(2.34%)
Day’s Range― - ―
52-Week Range$2.43 - $4.83
Previous Close$3.86
Volume360.03K
Average Volume (3M)1.10M
Market Cap
$298.43M
Enterprise Value$458.70M
Total Cash (Recent Filing)$207.97M
Total Debt (Recent Filing)$77.22M
Price to Earnings (P/E)―
Beta1.27
Next Earnings
Oct 29, 2026EPS Estimate
-0.18Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.20
Shares Outstanding99,146,740
10 Day Avg. Volume612,602
30 Day Avg. Volume1,095,280
Financial Highlights & Ratios
PEG Ratio0.03
Price to Book (P/B)0.91
Price to Sales (P/S)4.82
P/FCF Ratio-1.91
Enterprise Value/Market Cap1.54
Enterprise Value/Revenue28.95
Enterprise Value/Gross Profit35.64
Enterprise Value/Ebitda-5.75
Forecast
1Y Price Target
$11.00Price Target Upside163.79% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
EPS Forecast (FY)-0.65
Revenue Forecast (FY)$15.98M
Bulls Say, Bears Say
Bulls Say
Revenue And Gross MarginStrong top-line growth and high gross margins indicate improving commercial economics for the current business. If revenue continues scaling, this margin profile could provide meaningful contribution toward development costs and gradually narrow the gap between product revenue and operating expenses.
Low Current LeverageThe reported balance sheet shows substantial equity relative to current debt, giving X4 a stronger financial base than in 2024. This reduces immediate leverage pressure and preserves flexibility to fund clinical development and commercial preparation while the pipeline advances.
Regulatory And Pipeline ProgressFDA alignment on the pivotal 4WARD design reduces development uncertainty and supports a more efficient path for mavorixafor in chronic neutropenia. The program’s progress toward enrollment and future topline data strengthens the lead asset’s strategic and commercial potential.
Bears Say
Persistent Cash BurnX4 continues to consume substantial cash in operations and development, with negative operating and free cash flow closely tracking its losses. Unless revenue scales materially or spending declines, continued external financing will remain important to sustain the business.
Deep Operating LossesThe current revenue base remains far below the cost structure required to operate the company, producing deeply negative operating and net margins. This weak profitability limits internally funded growth and leaves future earnings dependent on successful commercialization and expense control.
New Secured Financing ObligationsThe $150 million facility improves liquidity but adds variable interest, paid-in-kind accruals, secured claims, and financial covenants. These obligations can increase the eventual repayment burden and constrain flexibility if clinical progress, revenue, or market capitalization targets are not achieved.
X4 Pharmaceuticals News
XFOR FAQ
What was X4 Pharmaceuticals Inc’s price range in the past 12 months?
X4 Pharmaceuticals Inc lowest stock price was $2.43 and its highest was $4.83 in the past 12 months.
What is X4 Pharmaceuticals Inc’s market cap?
X4 Pharmaceuticals Inc’s market cap is $298.43M.
When is X4 Pharmaceuticals Inc’s upcoming earnings report date?
X4 Pharmaceuticals Inc’s upcoming earnings report date is Oct 29, 2026 which is in 7 days.
How were X4 Pharmaceuticals Inc’s earnings last quarter?
X4 Pharmaceuticals Inc released its earnings results on Aug 06, 2026. The company reported -$0.13 earnings per share for the quarter, beating the consensus estimate of -$0.176 by $0.046.
Is X4 Pharmaceuticals Inc overvalued?
According to Wall Street analysts X4 Pharmaceuticals Inc’s price is currently Undervalued.
Does X4 Pharmaceuticals Inc pay dividends?
X4 Pharmaceuticals Inc does not currently pay dividends.
What is X4 Pharmaceuticals Inc’s EPS estimate?
X4 Pharmaceuticals Inc’s EPS estimate is -0.18.
How many shares outstanding does X4 Pharmaceuticals Inc have?
X4 Pharmaceuticals Inc has 99,146,740 shares outstanding.
What happened to X4 Pharmaceuticals Inc’s price movement after its last earnings report?
X4 Pharmaceuticals Inc reported an EPS of -$0.13 in its last earnings report, beating expectations of -$0.176. Following the earnings report the stock price went up 11.271%.
Which hedge fund is a major shareholder of X4 Pharmaceuticals Inc?
Currently, no hedge funds are holding shares in XFOR
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
X4 Pharmaceuticals Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$11.00 (163.79% Upside)
$11.00 (163.79% Upside)
Blogger Sentiment
Bullish
XFOR Sentiment 60%
Sector Average 67%
Sector Average 67%
Hedge Fund Trend
Increased
By 1.2M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $307.9K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Negative
Last 7 Days ▲ 1.6%
Last 30 Days ▼ 2.6%
Last 30 Days ▼ 2.6%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-4.14%
12-Months-Change
Fundamentals
Return on Equity
-63.05%
Trailing 12-Months
Asset Growth
140.63%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
X4 Pharmaceuticals Inc
X4 Pharmaceuticals, Inc. is a biopharmaceutical firm committed to the discovery, development, and commercialization of innovative therapies for uncommon immune system disorders. Its primary drug candidate, XOLREMDI (also known as mavorixafor), is an orally administered, small-molecule antagonist specifically designed to target the chemokine receptor CXCR4. This compound is currently undergoing Phase 3 clinical trials for the management of WHIM syndrome, a rare immunodeficiency characterized by symptoms such as warts, hypogammaglobulinemia, recurrent infections, and myelokathexis. To broaden its global presence, the company has entered into several licensing agreements: A partnership with Abbisko Therapeutics Co Ltd. grants rights for the manufacturing and distribution of XOLREMDI in mainland China, Taiwan, Hong Kong, and Macau. Another agreement with Norgine covers the development, production, and commercialization of mavorixafor across Europe, Australia, and New Zealand. Furthermore, X4 Pharmaceuticals holds a comprehensive agreement with Genzyme Corporation concerning the CXCR4 receptor, allowing for the development and commercialization of licensed compounds for all medical applications, including therapeutic, preventive, and diagnostic uses. The company maintains its corporate headquarters in Boston, Massachusetts.
XFOR Stock 12 Month Forecast
Average Price Target
$11.00
▲(163.79% Upside)
Technical Analysis
Ownership Overview
0.78% Insiders
15.34% Mutual Funds
0.01% Other Institutional Investors
76.03% Public Companies and
Individual Investors